Signaturefd LLC Grows Stock Holdings in IDEAYA Biosciences, Inc. $IDYA

Signaturefd LLC boosted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 58.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,549 shares of the company’s stock after purchasing an additional 1,672 shares during the period. Signaturefd LLC’s holdings in IDEAYA Biosciences were worth $96,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. CWM LLC boosted its stake in shares of IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after buying an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of IDEAYA Biosciences by 180.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock valued at $39,000 after purchasing an additional 1,546 shares during the period. Parallel Advisors LLC increased its position in shares of IDEAYA Biosciences by 72.4% during the 2nd quarter. Parallel Advisors LLC now owns 3,260 shares of the company’s stock valued at $69,000 after purchasing an additional 1,369 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of IDEAYA Biosciences by 46.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock worth $109,000 after purchasing an additional 2,112 shares during the period. Finally, GAMMA Investing LLC lifted its stake in shares of IDEAYA Biosciences by 2,490.9% in the 1st quarter. GAMMA Investing LLC now owns 7,125 shares of the company’s stock worth $1,170,000 after purchasing an additional 6,850 shares during the period. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

Shares of IDYA stock opened at $27.64 on Friday. The stock has a 50 day moving average price of $25.04 and a 200 day moving average price of $21.50. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $32.67. The firm has a market capitalization of $2.42 billion, a P/E ratio of -7.29 and a beta of 0.14.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The firm had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $3.48 million. During the same period in the previous year, the company earned ($0.68) earnings per share. The business’s quarterly revenue was up NaN% on a year-over-year basis. As a group, sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on IDYA. Oppenheimer set a $36.00 target price on shares of IDEAYA Biosciences and gave the company an “outperform” rating in a report on Monday, September 8th. Citizens Jmp began coverage on IDEAYA Biosciences in a research note on Thursday, September 4th. They issued a “mkt outperform” rating and a $41.00 price objective for the company. The Goldman Sachs Group upgraded IDEAYA Biosciences to a “hold” rating and set a $25.00 target price on the stock in a research report on Thursday, July 10th. Royal Bank Of Canada boosted their price target on IDEAYA Biosciences from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Tuesday, September 9th. Finally, Barclays began coverage on IDEAYA Biosciences in a research note on Thursday, September 4th. They issued an “overweight” rating and a $40.00 price objective on the stock. Fourteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, IDEAYA Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.36.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.